AHA comments on DEA’s proposed rule on controlled substances quotas

May 4, 2018

Re: Docket No. DEA-480, Controlled Substances Quotas; Notice of Proposed Rulemaking (Vol. 83, No. 76), April 19, 2018.

We concur with the DEA that setting quotas for the production of opioid medications can be an effective step in “preventing the accumulation of controlled substances in amounts exceeding legitimate need,” and therefore reduce the chance that these powerful medications will be diverted for non-medical illicit purposes. However, opioids are commonly administered in hospitals to relieve the pain of significant trauma, surgery, cancer that has metastasized to the bone or invaded the brain, severe burns and other significant diseases or disorders.

Given its commitment to addressing injectable opioid shortages, the AHA strongly recommends that the DEA amend its proposed rule to ensure that, in addition to diversion, that drug shortages be considered when aggregate production quotas are set and adjusted.

We also recommend that the DEA routinely consult with the Food and Drug Administration’s drug shortage staff, which collects and publishes relevant data on all national drug shortages, when establishing and adjusting quotas.


Read the full comment letter below.

Related Resources

Letter
Letter to the Senate Finance Committee leadership supporting the Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018.
Other Resources
Member
This edition covers an advocacy update, resources for Mental Health Awareness month, and more. 
Advisory
Member
On April 24, the Centers for Medicare…
Advisory
Member
On May 8, the Centers for Medicare…
Letter
Public
AHA's comment on the CMS proposed rule to amend requirements that states assess their Medicaid fee-for-service provider payments to determine if they are…
Letter
Public
AHA comments to HRSA regarding proposed rule that would further delay the effective date for implementing final regulations regarding the 340B Drug Pricing…